ADVFN Logo ADVFN

No pudimos encontrar ningún resultado para:
Asegúrate de que la ortografía sea correcta o intenta ampliar tu búsqueda.

Tendencias Ahora

Listas Principales

Parece que no has iniciado sesión.
Haz clic en el botón de abajo para iniciar sesión y ver tu historial reciente.

Regístrate

¿Ya eres miembro? Iniciar sesión

Los Principales Corredores en Línea

Más Corredores en Línea

Datos
Noticias
Herramientas
Mercados
Descubrir

Hot Features

Follow Feed

Conéctese con traders e inversores en nuestra comunidad Follow Feed.

Flujo de Opciones

Explora datos de opciones completos y utiliza filtros avanzados con Options Flow.

Monitor

Organiza y monitorea tu lista de seguimiento de acciones y activos con Monitor.
Iniciar Sesión Premium IconPremium Help Menu
S&P 500
5,273.08
-0.64%
Dow Jones
39,100.55
-1.44%
US Dollar vs MXN
16.72308
0.35%
Brent Oil
80.885
-0.79%
Bitcoin
67,520.70
-2.29%
Registration Strip Icon for default Regístrate gratis para obtener cotizaciones en tiempo real, gráficos interactivos, flujo de opciones en vivo y más.
Regístrate
  1. Inicio
  2. Invertir
  3. Acciones
  4. Estados Unidos
  5. NASDAQ
  6. Urovant Sciences Ltd (UROV)

  7. Urovant Sciences Ltd (UROV) Noticias

UROV

Urovant Sciences (UROV)

Urovant Sciences Ltd
Fecha:
Ordernar por:
 Showing the most relevant articles for your search:NASDAQ:UROV
FechaHoraFuenteTítuloSímboloCompañía
13/04/202211:02Business WireUrovant Sciences to Present Interim Data from Phase 2a Study of Potential Novel Gene Therapy, URO-902, and New Analyses of Data from Phase 3 EMPOWUR Extension Trial of GEMTESA® (vibegron) 75 mg at 2022 American Urological Association Annual MeetingNASDAQ:UROVUrovant Sciences Ltd
07/03/202210:56Business WireUrovant Sciences Announces Positive Topline Results of Phase 2a Trial of its Potential Novel Gene Therapy, URO-902NASDAQ:UROVUrovant Sciences Ltd
20/12/202111:11Business WireUrovant Sciences Announces Publication in Advances in Therapy of Analyses of Patient-Perceived Meaningfulness of Improvement in Symptom Reduction for Overactive Bladder Patients Treated with GEMTESA® (vibegron) 75 mgNASDAQ:UROVUrovant Sciences Ltd
08/11/202107:00Business WireUrovant Sciences Announces Publication in Blood Pressure Monitoring of Positive Ambulatory Blood Pressure Study Results for GEMTESA® (vibegron) 75 mg in Overactive Bladder PatientsNASDAQ:UROVUrovant Sciences Ltd
01/04/202105:14Edgar (US Regulatory)Notice of Effectiveness (effect)NASDAQ:UROVUrovant Sciences Ltd
31/03/202111:31Edgar (US Regulatory)Statement of Changes in Beneficial Ownership (4)NASDAQ:UROVUrovant Sciences Ltd
30/03/202111:13Edgar (US Regulatory)Amended Statement of Beneficial Ownership (sc 13d/a)NASDAQ:UROVUrovant Sciences Ltd
29/03/202114:13Edgar (US Regulatory)Post-effective Amendment to an S-8 Filing (s-8 Pos)NASDAQ:UROVUrovant Sciences Ltd
29/03/202114:04Edgar (US Regulatory)Post-effective Amendment to Registration Statement (pos Am)NASDAQ:UROVUrovant Sciences Ltd
29/03/202107:44Edgar (US Regulatory)Notification Filed by National Security Exchange to Report the Removal From Listing and Registration of Matured, Redeemed or ...NASDAQ:UROVUrovant Sciences Ltd
29/03/202107:36Edgar (US Regulatory)Current Report Filing (8-k)NASDAQ:UROVUrovant Sciences Ltd
19/02/202105:11Edgar (US Regulatory)Amended Statement of Ownership: Private Transaction (sc 13e3/a)NASDAQ:UROVUrovant Sciences Ltd
19/02/202105:05Edgar (US Regulatory)Proxy Statement - Merger or Acquistion (definitive) (defm14a)NASDAQ:UROVUrovant Sciences Ltd
16/02/202114:38Edgar (US Regulatory)Amended Statement of Ownership (sc 13g/a)NASDAQ:UROVUrovant Sciences Ltd
12/02/202116:43Edgar (US Regulatory)Quarterly Report (10-q)NASDAQ:UROVUrovant Sciences Ltd
12/02/202115:05Business WireUrovant Sciences Provides Merger Update and Reports Third Quarter Fiscal Year 2020 ResultsNASDAQ:UROVUrovant Sciences Ltd
11/02/202107:00Business WireUrovant Sciences Announces Progression of URO-902 Phase 2a Trial Following Positive Recommendation from the Data & Safety Mon...NASDAQ:UROVUrovant Sciences Ltd
02/02/202105:08Edgar (US Regulatory)Proxy Soliciting Materials (revised) (prer14a)NASDAQ:UROVUrovant Sciences Ltd
23/12/202015:05Business WireUrovant Sciences Announces U.S. FDA Approval of GEMTESA® (vibegron) 75 mg Tablets for the Treatment of Patients with Overact...NASDAQ:UROVUrovant Sciences Ltd
24/11/202015:05Business WireUrovant Sciences Announces Topline Data from Phase 2a Study of Vibegron for the Treatment of Irritable Bowel Syndrome (IBS) P...NASDAQ:UROVUrovant Sciences Ltd
19/11/202007:00Business WireUrovant Sciences Announces Positive Clinical Efficacy and Safety Data from Vibegron EMPOWUR Long Term Extension StudyNASDAQ:UROVUrovant Sciences Ltd
16/11/202005:30Edgar (US Regulatory)Additional Proxy Soliciting Materials (definitive) (defa14a)NASDAQ:UROVUrovant Sciences Ltd
13/11/202008:36Dow Jones NewsDisney, DraftKings, Palantir, Li Auto: What to Watch When the Stock Market Opens TodayNASDAQ:UROVUrovant Sciences Ltd
12/11/202016:18Business WireUrovant Sciences Enters Into Definitive Agreement for Sumitovant Biopharma to Acquire All Outstanding SharesNASDAQ:UROVUrovant Sciences Ltd
12/11/202016:00PR Newswire (US)Sumitovant Biopharma and Urovant Sciences Announce Sumitovant's Acquisition of Remaining Stake in UrovantNASDAQ:UROVUrovant Sciences Ltd
10/11/202007:00Business WireUrovant Sciences to Present at the Jefferies Virtual London Healthcare ConferenceNASDAQ:UROVUrovant Sciences Ltd
02/11/202015:05Business WireUrovant Sciences Reports Second Quarter Fiscal Year 2020 ResultsNASDAQ:UROVUrovant Sciences Ltd
27/10/202007:00Business WireUrovant Sciences to Report Second Fiscal Quarter 2020 Financial ResultsNASDAQ:UROVUrovant Sciences Ltd
07/10/202007:00Business WireUrovant Sciences Announces Co-Promotion Agreement for Vibegron with Sunovion PharmaceuticalsNASDAQ:UROVUrovant Sciences Ltd
08/09/202007:00Business WireUrovant Sciences to Present at the H.C. Wainwright & Co. Annual Global Investment ConferenceNASDAQ:UROVUrovant Sciences Ltd
 Showing the most relevant articles for your search:NASDAQ:UROV

Su Consulta Reciente

NASDAQ
NVDA
NVIDIA
CCOM
US30
US 30
SPI
SP500
S&P 500
FX
EURUSD
Euro vs US Dollar
USI
USTECH100
US Tech 100
AMEX
XLV
Health Care Select Sector
NASDAQ
GOOGL
Alphabet
COIN
ETHUSD
Ethereum
NYSE
NKE
Nike
USOTC
RHHBY
Roche (QX)
FX
EURMXN
Euro vs MXN
NYSE
CVX
Chevron
USOTC
BASFY
BASF (QX)
FX
USDMXN
US Dollar vs MXN
CCOM
US500
US 500
Delayed Upgrade Clock
ADVFN Logo

México
Empresa
Negocios
Popular
Obtener la aplicación

Soporte: (55) 4170 8128 | soporte@advfn.mx

Al acceder a los servicios disponibles de ADVFN usted acepta quedar sujerto a los Términos y Condiciones

© 2024 ADVFN PLC - Todos los derechos reservados